1. Executive Summary (Confidence: High)

Oviva has established itself as a dominant force in the European longevity and chronic care landscape, having treated over 800,000 patients across Switzerland, the UK, Germany, France, and Poland. Founded in 2014 by Kai Eberhardt and Manuel Baumann, the organization addresses the multi-billion dollar economic and health burden of metabolic disease through a "virtual chronic care layer" that sits inside public healthcare systems. Oviva is structurally unique for its high level of clinical validation, with over 90 peer-reviewed studies supporting its methodology, and its success in achieving formal regulatory status as a "DiGA" (Digital Health Application) in Germany and a recommended provider for the NHS in the UK. With a total funding base that was significantly augmented by a $220 million Series D in late 2025, led by Kinnevik, Oviva is scaling its operations to provide population-wide productivity benefits and reduce the long-term specialty care costs associated with complex obesity.